4519.T
EquityCHUGAI PHARMACEUTICAL CO
Health Care · Drug Manufacturers - General
$9,757.00
+9,757.00 (+0.00%)
Open
N/A
Day Range
$9,603.00 - $9,822.00
52W Range
$5,942.00 - $10,700.00
Volume
3M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Netflix Adds Amazon, Yahoo Audience Targeting to Ad Platform
Michelangelo's works hidden in 'secret room', researcher says
Bank of Canada's Governor Warns of Increased Risks From New Credit Players in Debt Markets
Why BigBear.ai Stock Plummeted 21.4% Last Month and Is Falling in March
Oil Price Shock Could Delay Fed Rate Cuts, Morgan Stanley Says
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | $233.86 | N/A | 2.84% | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.27 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $22.50 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| CRSP | CRISPR Therapeutics AG | $59.17 | N/A | - | +0.00% |
| AHCO | AdaptHealth Corp. | $9.72 | N/A | - | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.66 | N/A | - | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.68 | N/A | - | +0.00% |
About CHUGAI PHARMACEUTICAL CO
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
www.chugai-pharm.co.jp →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+177.6%
3Y CAGR
+51.6%
5Y CAGR
N/A
10Y CAGR
N/A
Loading financial data...
Revenue & Earnings
No financial statement data available for 4519.T.